(Sandhya Jha, Intern Journalist): Good news comes from the US in the first phase trial of an ongoing vaccine to stop the coronavirus-spread pandemic Covid-19. The first corona vaccine trials conducted here on humans have yielded very positive results.
Moderna, a Boston-based biotech company that manufactures it, said Monday evening that participants who had been tested for their mRNA vaccine had better-than-expected immunity in their bodies and side effects were minor.
The news stirred Wall Street and the S&P 500 US Benchmark Equity Index climbed 3 percent in afternoon trade. With this, Moderna’s stock jumped nearly 30 percent and the stock price jumped from $ 66 to $ 87.
Effect of vaccine safe and tolerable
On Monday, Moderna spoke of the interim results of the preliminary phase trial. Accordingly, the candidate given this vaccine named mRNA-1273 had only minor side effects in the body and the vaccine’s effect was found to be safe and tolerable.
Moderna said that the immune system of the vaccine-receiving candidates was found to be equal to or more powerful than the patients recovered from Covid-19 in fighting the virus. Moderna CEO Stéphane Bancel said they could not have expected better data from it.
First company to be tested on humans in 42 days
Modera is the first American company to overtake everyone in the vaccine race. The company completed the journey from getting the genetic code required for the vaccine to its trial in humans in just 42 days. It was also the first time that trials had been started in humans before animals.
On March 16, the vaccine was first applied to a 43-year-old woman named Jennifer, the mother of two children, at the Kaiser Permanent Research Facility in Seattle. The first trial included 45 healthy participants aged between 18 and 55 years old. Of these, 8 were initially vaccinated.
Minor side effects in early stage
Moderna’s chief medical officer Tal Zaks said the results showed that the immune system responded well to combat natural infections, even when small doses of the vaccine were given. Based on these results and the data found after a study done on mice, the company is now planning to do further trials with less dose.
They reported that there were side-effects in the initial phase of the trial that are common to many vaccines, such as – some people experience redness and coldness at the injection site. These data confirmed our belief that mRNA-1273 has the ability to inhibit Covid-19.
Mordana’s share rises three-fold
Moderna Company’s share price has more than tripled since February and has risen 240 percent over Friday’s closing level. In premarket trading, Moderna’s stock opened at $ 86.14 against Friday’s closing price of $ 66.69.
The successful trial of the coronavirus vaccine enlivened investors in the Nasdaq market so that the stock jumped above 25 percent and was once seen at a level of $ 87 per share, rising 30 percent.